Global ADC Drug Development & China Opportunities

ADC is emerging as one of the most active spaces in cross-border transactions, with numerous notable China out-licenses on the horizon. 

• Merck Expands ADC Footprint with $9.3B Kelun Licensing Deal 

• Elevation Oncology Strikes an ADC Licensing Deal with CSPC 

• DAC Announces License Agreement with Janssen for Novel ADCs 

• ADC Therapeutics and Overland Pharma Form Strategic JV to Expand ADC Drug Development in China and Singapore, Advised by MSQ Ventures 

This webinar co-hosted by MSQ Ventures and BAW, provides a unique opportunity to gain exclusive insights and knowledges on the Global ADC Drug Development & China Opportunities, from top industry leaders and dealmakers. The discussions will cover the latest trends and developments in the fast-growing and highly innovative ADC space, enabling attendees to stay ahead of the curve and make informed business decisions in this dynamic field. 

Moderator:

• Echo Hindle-Yang, Founder & CEO, MSQ ventures 

Panelists: 

• Robert Zhao, CEO, DAC Biotechnology

• Nikhil Mutyal, Executive Director, BD&L, Merck 

• John Adamou, CBO, CSPC Pharmaceutical 

• Ziping Wei, CEO, Bliss Biopharmaceutical 

DATE: Tuesday, March. 28th, 2023  
TIME: 8:00 – 9:00 am EST  
LOCATION: Zoom
REGISTRATION: https://lnkd.in/eWTzP8Ge